<DOC>
	<DOCNO>NCT00335192</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic interaction NRTI 3TC ABV , TDF nucleotide . For purpose , intracellular plasma level 3TC ABV compare patient give nucleoside TDF 30 day interruption TDF .</brief_summary>
	<brief_title>To Determine There Are Pharmacokinetic Interactions Plasma Intracellular Level Between Nucleosides Tenofovir</brief_title>
	<detailed_description>There clear evidence pharmacokinetic interaction ddI+TDF . However , interaction TDF NRTIs , mainly intracellular level , well study . Since NRTIs anabolized intracellular level numerous kinase , transport passive carrier system , interaction may TDF NRTIs . This study aim investigate pharmacokinetic interaction TDF nucleoside abacavir ( ABV ) lamivudine ( 3TC ) plasma intracellular level . With objective , intracellular plasma level analyse group patient receive combination 3TC +TDF , ABV+TDF 3TC+ABV+TDF together lopinavir/rtv nevirapine . Subsequently , second phase study , group patient give ABV and/or 3TC + TDF + lopinavir/rtv , pharmacokinetic determination repeat 4-week interruption TDF .</detailed_description>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>1 . HIV+ patient age 18 year . 2 . Undetectable HIV viral load last determination 3 . Patients capable correct compliance accord clinical criterion . 4 . Patients triple HAART therapy previous 3 month include 3TC and/or ABV TDF , PI ( Lopinavir/ritonavir ) NNRTI ( Nevirapine ) 5 . Women may fertile age ( define least one year menopause undergoing surgical sterilisation technique ) , must undertake use barrier contraceptive method study . 6 . Ability provide inform consent . 1 . Incorrect therapeutic compliance four week begin study . 2 . Interruption withdrawal therapy followup . 3 . Concomitant treatment drug accord clinician 's criterion may interact investigational antiretrovirals , antiretrovirals . 4 . Triple HAART therapy include Nevirapine ( phase II ) 5 . Documented suspect resistance ABV , 3TC lopinavir/rtv ( phase II ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Intracellular concentration</keyword>
	<keyword>Plasma concentration</keyword>
	<keyword>Abacavir</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>Lamivudine ( 3TC )</keyword>
	<keyword>Pharmacokinetic interaction</keyword>
</DOC>